gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PACBHealthcareLab Analytical Instruments

Pacific Biosciences of California, Inc. (PACB)

$2.55+4.51%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.67▲ 33.75% in range
Nov 4, 2025Low $1.11 · High $2.90Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Pacific Biosciences of California closed at $2.55 on Nov 4, up 4.51%, 12.1% below its 52-week closing high. Volume of 21.0M shares was 1.59× its 20-day average (above normal).

Split-adjusted performance: -5.6% over one month, +49.1% over six months, +13.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $39.01M, down 1.9% from a year earlier, with a net margin of -114.7%.

Short interest was 46.9M shares at the Oct 15 settlement (18.2% of float, 2.2 days to cover).

Market cap$792.6M310.8M shares
Revenue · quarter$39.0M−1.9% YoY
Diluted EPS$-0.14—
P/E · TTM—P/S 5.0×
Net margin-114.7%Gross 32.4%
Dividend yieldNone
52-week range1.11 – 2.90−12.1% from high
Volume21.0M1.59× 20-day avg
Volatility · 60d116.6%Annualised
Short % of float18.2%2.2 days to cover
Net cash-$407.5MCash $236.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.9%1M −5.6%3M +118.9%6M +49.1%YTD +36.4%1Y +13.8%3Y −64.1%5Y −90.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum65
Revenue growth21
Net margin29
Value (low P/E)—
Size52

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short46.9M−0.6% vs prior
Days to cover2.2Settled Oct 15
% of float18.2%
Short vol. 10d56.5%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PACBPacific Biosciences of California$2.55+4.51%+49.1%−1.9%−114.7%—$792.6M
CTKBCytek Biosciences$5.88−1.34%+19.0%+5.6%−25.3%—$764.3MCompare
MASS908 Devices$11.07+3.75%+37.3%+23.3%−74.0%—$457.6MCompare
ALMRAlamar Biosciences$27.39−9.36%——−44.9%—$1.90BCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
TXG10x Genomics$67.52+3.42%+196.9%−12.6%−11.9%—$8.80BCompare
BRKRBruker$63.79+12.90%+50.8%+5.2%−7.5%—$9.72BCompare

News about Pacific Biosciences of California

All news →
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key FactsZacks Investment Research · 6d agoNeutralPacific Biosciences of California (PACB) Declines More Than Market: Some Information for InvestorsZacks Investment Research · Oct 14, 2026▼ NegativePacBio Teams With TychoBio to Advance AI-Driven RNA TherapeuticsZacks Investment Research · Oct 13, 2026▲ PositiveWhy Pacific Biosciences of California (PACB) Dipped More Than Broader Market TodayZacks Investment Research · Oct 8, 2026▼ NegativePacific Biosciences of California (PACB) Rises Higher Than Market: Key FactsZacks Investment Research · Oct 2, 2026▼ Negative

Quick answers

What does Pacific Biosciences of California do?
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis.
What is PACB's market cap?
$792.62M, based on the Nov 4 close of $2.55.
Does Pacific Biosciences of California pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PACB is sold short?
46.9M shares, 18.2% of float, as of Oct 15, 2026.
What sector is PACB in?
Healthcare, in the Lab Analytical Instruments industry.

About Pacific Biosciences of California

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

HQ: Menlo Park, CA485 employeesListed Oct 27, 2010pacb.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology